Physician profile
David D Nelsen
NPI 1417184169
$1,076,773.33
in general payments reported to CMS, 2019-2025
26 companies · $203K in 2025
The $203K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210K · 2020: $48K · 2021: $134K · 2022: $110K · 2023: $189K · 2024: $182K · 2025: $203K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $425K · Consulting Fee: $51K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $45K · Travel and Lodging: $39K · Food and Beverage: $13K · Education: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $424,845.83 |
| Consulting Fee | $51,372.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $44,880.00 |
| Travel and Lodging | $38,722.84 |
| Food and Beverage | $13,477.95 |
| Education | $768.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424,141.64 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $358,903.89 | 2019-2025 | Ilumya, Winlevi |
| Amgen INC. | $133,525.24 | 2019-2025 | Otezla, Otezla |
| Celgene Corporation | $66,200.30 | 2019 | |
| Arcutis Biotherapeutics, INC. | $37,828.45 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $37,014.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $10,127.62 | 2022-2025 | Sotyktu |
| Incyte Corporation | $5,785.30 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $910.19 | 2021-2025 | Dupixent |
| Genzyme Corporation | $547.09 | 2019-2023 | |
| Leo Pharma INC. | $377.81 | 2024-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $370.80 | 2019-2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $243.00 | 2021-2024 | |
| Ucb, INC. | $225.83 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $186.05 | 2021-2025 | Olumiant, Taltz, Zepbound |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $102.29 | 2023-2024 | Vtama |
| Blueprint Medicines Corporation | $61.07 | 2025 | |
| Galderma Laboratories, L.P. | $39.40 | 2025 | Nemluvio |
| Organon LLC | $36.59 | 2023-2025 | Hadlima, Vtama |
| Verrica Pharmaceuticals INC. | $30.71 | 2024 | Ycanth |
| Celltrion USA INC. | $30.30 | 2023 | Yuflyma |
| Sandoz INC. | $21.83 | 2023 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $19.62 | 2023 | Tremfya |
| Pfizer INC. | $16.93 | 2023 | |
| Genentech USA, INC. | $14.78 | 2022 | |
| Strata Skin Sciences, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nelsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.